Epigenetics is a new area of biology providing novel opportunities for the treatment of human diseases
Drug development in the field of epigenetics is directed towards the identification of small molecules that inhibit the activities of proteins that add, remove or recognize various chemical modifications to specific sites on DNA or chromosomal proteins. These marks play a key role in determining whether a gene is on or off. Epigenetic regulators are often referred to as writers, erasers and readers. Research at Constellation and by others has shown that abnormal epigenetic regulation contributes to many different diseases.
Constellation’s research is focused on each of the major pillars of epigenetic regulation –
chromatin writers, erasers, and readers
Each of these protein classes provides a rich collection of targets with strong disease association. We have developed drug discovery platforms in each class to enable the development of novel medicines that modulate these important targets. Constellation has made significant progress in discovering and developing compelling drug candidates derived from our broad platform of capabilities applied to these three classes of epigenetic targets.
Build the premier chromatin therapeutics company by discovering and developing drugs that target epigenetic function and associated disease biology
In order to accomplish this mission, we weave our core values (FIRST values) into everything that we do.
Focus on serving unmet medical needs of patients
Respect, collaborate, innovate, enjoy what we do
Scientific breakthroughs are our passion
Teach, listen to, and learn from each other
Constellation has two clinical-stage oncology development programs.
CPI-0610 is a small molecule that inhibits the expression of several genes involved in cancer. One of the genes targeted by CPI-0610 is called MYC, which is frequently overexpressed ("turned on") in both blood cancers and some solid tumors.